Aprepitant (EMEND): the role of substance P in nausea and vomiting.

  • Prommer E
ISSN: 1536-0288
Citations of this article
Mendeley users who have this article in their library.


Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.




Prommer, E. (2005). Aprepitant (EMEND): the role of substance P in nausea and vomiting. Journal of Pain & Palliative Care Pharmacotherapy, 19(3), 31–9. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16219609

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free